Warning People About Prescription Drugs

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

r218533_8550258For years, Americans have assumed that the FDA was set up to test drugs. If a treatment was not effective or was too dangerous for patients, it never made it to market. If drugs that were released had side effects, those were disclosed to doctors and hospitals. The system do not work perfectly and some patients were sickened or killed by drugs with unanticipated problems. But, in general, the public could assume that the FDA was its pharma guardian angel.

It may be that the FDA has not been telling patients everything it knows, or has been too circumspect in its disclosures. According to The New York Times, “researchers at the Dartmouth Medical School are urging federal regulators to adopt a … concept — numerical tables that quantify the benefits of taking a drug compared with a placebo, and that list the odds of having side effects.”

And, all along people thought that the FDA and their doctors were aware of all the medical risks of every drug on the market and would always be obligated to pass those on to their patients.

Even the suggestion of such a “disclosure” program speaks volumes about how poor a job the FDA has done in protecting the interests of people who need drugs and medical devices to cure diseases or have better lives. As it turns out, that was not entirely true. A patient who is not willing to read a label with the pluses and minuses of a treatment gets to play Russian roulette with his physician.

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618